Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
About this item
Full title
Author / Creator
Cortes, Javier , Rugo, Hope S. , Cescon, David W. , Im, Seock-Ah , Yusof, Mastura M. , Gallardo, Carlos , Lipatov, Oleg , Barrios, Carlos H. , Perez-Garcia, Jose , Iwata, Hiroji , Masuda, Norikazu , Torregroza Otero, Marco , Gokmen, Erhan , Loi, Sherene , Guo, Zifang , Zhou, Xuan , Karantza, Vassiliki , Pan, Wilbur and Schmid, Peter
Publisher
Boston: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Boston: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
AbstractBackgroundIn an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score (CPS; the number of PD-L...
Alternative Titles
Full title
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2692071888
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2692071888
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2202809
